fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

High levels of antihistamine drugs can reduce fitness gains

Written by | 3 Jul 2025

For some, the word “histamine” might evoke thoughts of seasonal allergies: runny noses, scratchy throats and itchy eyes. But the molecule also influences exercise performance. A new study… read more.

KalVista highlights clinical and real-world advances in HAE at EAACI Congress 2025

Written by | 8 Jun 2025

KalVistA Pharmaceuticals Inc. announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom… read more.

Connect Biopharma to present positive Rademikibart data in type 2 asthma at EAACI 2025

Written by | 7 Jun 2025

Connect Biopharma Holdings Limited (a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations… read more.

European approval for Itulazax (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents – ALK

Written by | 5 Jun 2025

ALK-Abello announced that its European regulatory filing for Itulazax (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been… read more.

Daily doses of peanuts tackle allergic reactions in adults

Written by | 6 May 2025

The first clinical trial to test whether adults allergic to peanuts can be desensitised has shown great success with two thirds of the cohort consuming the equivalent of… read more.

FDA approves neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis) – ARS Pharma

Written by | 23 Apr 2025

The FDA approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who… read more.

Successful penicillin allergy de-labelling

Written by | 24 Mar 2025

29th EAHP Congress highlights Approximately 10% of inpatients are labelled as ‘allergic to penicillin’ but the vast majority have not experienced a true allergic reaction. Having a penicillin… read more.

Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies – Roche

Written by | 15 Mar 2025

Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further evidence supporting the… read more.

FDA has approved Odactra tablet for use in young children with house dust mite allergy – ALK

Written by | 12 Mar 2025

ALK announced that the FDA has approved ALK’s Odactra tablet for use in young children with house dust mite (HDM) allergy.Odactra is now indicated to treat HDM-induced allergic… read more.

Penicillin allergy delabeling in syphilis patients assists in furthering treatment

Written by | 28 Oct 2024

About 10% of Americans believe they are allergic to penicillin, and approximately 90% of those patients are not actually allergic. As a result, those with the penicillin allergy… read more.

European Commission approves EUR Neffy (epinephrine nasal spray) for emergency treatment of severe allergic reactions in adults and children – ARS Pharma

Written by | 7 Sep 2024

ARS Pharmaceuticals, Inc. announced the European Commission’s approval of EURneffy for emergency treatment of severe allergic reactions in adults and children weighing at least 30 kilograms. This approval… read more.

UCB to accelerate innovation and strategic partnerships, divesting mature product portfolio in China to CBC Group.

Written by | 2 Sep 2024

UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.